nach oben

Erschienen in:

01.12.2012 | Original Article

Synergistic effects of low LDL cholesterol with other factors for the risk of cancer in type 2 diabetes: the Hong Kong Diabetes Registry

verfasst von: Xilin Yang, Wing Yee So, Ronald C. W. Ma, Alice P. S. Kong, Heung Man Lee, Gang Xu, Risa Ozaki, Juliana C. N. Chan

Erschienen in: Acta Diabetologica | Sonderheft 1/2012

Einloggen, um Zugang zu erhalten

Abstract

We have reported associations of cancer with low triglyceride and high high-density lipoprotein cholesterol (HDL-C) as well as co-presence of low low-density lipoprotein cholesterol (LDL-C) and albuminuria in type 2 diabetes (T2D). This analysis aims to test (1) whether low LDL-C and low triglyceride have synergistic effects to increase cancer risk in T2D and (2) whether high HDL-C enhances the effect of co-presence of low LDL-C and albuminuria on cancer risk. A prospective cohort of patients with T2D, established within the Prince of Wales Hospital, was used in the analysis. A total of 3,476 T2D patients in Hong Kong enrolled between 1996 and 2005, free of cancer at enrolment and not using statins or fibrates within 2.5 years before enrolment and during follow-up, were followed until 2005. The study measured additive interactions of low LDL-C with other factors for cancer using relative excess risk due to interaction (RERI) and attributable proportion due to interaction (AP). A statistically significant RERI > 0 or AP > 0 indicates additive interaction. During 5.11 years of follow-up, 199 patients developed cancer. Co-presence of triglyceride <1.70 mmol/L and LDL-C < 2.80 mmol/L was associated with increased cancer risk (multivariable hazard ratio [HR]:2.13, P = 0.0008) with significant interaction. Co-presence of HDL-C ≥ 1.30 mmol/L and LDL-C < 2.80 mmol/L plus albuminuria was also associated with increased cancer risk (HR: 3.84, P < 0.0001) with significant interaction. In T2D, low triglyceride may potentiate cancer risk associated with low LDL-C while high HDL-C enhances the synergistic effect of low LDL-C with albuminuria towards increased cancer risk.

Chan JC, Malik V, Jia W, Kadowaki T, Yajnik CS, Yoon KH et al (2009) Diabetes in Asia: epidemiology, risk factors, and pathophysiology. JAMA 301(20):2129–2140PubMedCrossRef

Yang X, So W, Ko GT, Ma RC, Kong AP, Chow CC et al (2008) Independent associations between low-density lipoprotein cholesterol and cancer among patients with type 2 diabetes mellitus. CMAJ 179(5):427–437PubMedCrossRef

Nicolucci A (2010) Epidemiological aspects of neoplasms in diabetes. Acta Diabetol 47(2):87–95PubMedCrossRef

Hirsch HA, Iliopoulos D, Joshi A, Zhang Y, Jaeger SA, Bulyk M et al (2010) A transcriptional signature and common gene networks link cancer with lipid metabolism and diverse human diseases. Cancer Cell 17(4):348–361PubMedCrossRef

Jafri H, Alsheikh-Ali AA, Karas RH (2010) Baseline and on-treatment high-density lipoprotein cholesterol and the risk of cancer in randomized controlled trials of lipid-altering therapy. J Am Coll Cardiol 55(25):2846–2854PubMedCrossRef

Perseghin G, Calori G, Lattuada G, Ragogna F, Dugnani E, Garancini MP et al. (2012) Insulin resistance/hyperinsulinemia and cancer mortality: the Cremona study at the 15th year of follow-up. Acta Diabetol. doi:10.1007/s00592-011-0361-2

Yang X, So WY, Ma RC, Ko GT, Kong AP, Wang Q et al (2008) Predicting values of lipids and white blood cell count for all-site cancer in type 2 diabetes. Endocr Relat Cancer 15(2):597–607PubMedCrossRef

Yang X, So WY, Ma RC, Kong AP, Lee HM, Yu LW et al (2011) Low HDL cholesterol, metformin use and cancer risk in type 2 diabetes: the Hong Kong Diabetes Registry. Diabetes Care 34(2):375–380PubMedCrossRef

Alsheikh-Ali AA, Trikalinos TA, Kent DM, Karas RH (2008) Statins, low-density lipoprotein cholesterol, and risk of cancer. J Am Coll Cardiol 50(5):409–418CrossRef

10.

Yang X, So WY, Ma RC, Ko GT, Kong AP, Zhao H et al (2009) Low LDL cholesterol, albuminuria, and statins for the risk of cancer in type 2 diabetes: the Hong Kong Diabetes Registry. Diabetes Care 32(10):1826–1832PubMedCrossRef

11.

Yang X, Ma RC, So WY, Yu LW, Kong AP, Ko GT et al (2011) Low triglyceride and nonuse of statins is associated with cancer in type 2 diabetes mellitus: the Hong Kong Diabetes Registry. Cancer 117(4):862–871PubMedCrossRef

12.

Annunziata M, Granata R, Ghigo E (2011) The IGF system. Acta Diabetol 48(1):1–9PubMedCrossRef

13.

Shimomura I, Bashmakov Y, Ikemoto S, Horton JD, Brown MS, Goldstein JL (1999) Insulin selectively increases SREBP-1c mRNA in the livers of rats with streptozotocin-induced diabetes. Proc Natl Acad Sci U S A 96(24):13656–13661PubMedCrossRef

14.

Smith TM, Gilliland K, Clawson GA, Thiboutot D (2008) IGF-1 induces SREBP-1 expression and lipogenesis in SEB-1 sebocytes via activation of the phosphoinositide 3-kinase/Akt pathway. J Invest Dermatol 128(5):1286–1293PubMedCrossRef

15.

Palozza P, Colangelo M, Simone R, Catalano A, Boninsegna A, Lanza P et al (2010) Lycopene induces cell growth inhibition by altering mevalonate pathway and Ras signaling in cancer cell lines. Carcinogenesis 31(10):1813–1821PubMedCrossRef

16.

Yang X, So WY, Ma RC, Kong AP, Xu G, Chan JC (2012) Diabetes and cancer: the mechanistic implications of epidemiological analyses from the Hong Kong Diabetes Registry. Diabetes Metab Res Rev. doi:10.1002/dmrr2287

17.

Rader DJ (2006) Molecular regulation of HDL metabolism and function: implications for novel therapies. J Clin Invest 116(12):3090–3100PubMedCrossRef

18.

Navab M, Anantharamaiah GM, Fogelman AM (2005) The role of high-density lipoprotein in inflammation. Trends Cardiovasc Med 15(4):158–161PubMedCrossRef

19.

Reuter S, Gupta SC, Chaturvedi MM, Aggarwal BB (2010) Oxidative stress, inflammation, and cancer: how are they linked? Free Radic Biol Med 49(11):1603–1616PubMedCrossRef

20.

Nakamura M, Onoda T, Itai K, Ohsawa M, Satou K, Sakai T et al (2004) Association between serum C-reactive protein levels and microalbuminuria: a population-based cross-sectional study in northern Iwate, Japan. Intern Med 43(10):919–925PubMedCrossRef

21.

Piwernetz K, Home PD, Snorgaard O, Antsiferov M, Staehr-Johansen K, Krans M (1993) For the DiabCare Monitoring Group of the St. Vincent Declaration Steering Committee. Monitoring the targets of the St. Vincent declaration and the implementation of quality management in diabetes care: the DiabCare initiative. Diabetic Med 10:371–377PubMedCrossRef

22.

Ma YC, Zuo L, Chen JH, Luo Q, Yu XQ, Li Y et al (2006) Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease. J Am Soc Nephrol 17(10):2937–2944PubMedCrossRef

23.

Friedewald WT, Levy RI, Fredrickson DS (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18(6):499–502PubMed

24.

Yang X, So WY, Tong PC, Ma RC, Kong AP, Lam CW et al (2008) Development and validation of an all-cause mortality risk score in type 2 diabetes. Arch Intern Med 168(5):451–457PubMedCrossRef

25.

Andersson T, Alfredsson L, Kallberg H, Zdravkovic S, Ahlbom A (2005) Calculating measures of biological interaction. Eur J Epidemiol 20(7):575–579PubMedCrossRef

26.

Li R, Chambless L (2007) Test for additive interaction in proportional hazards models. Ann Epidemiol 17(3):227–236PubMedCrossRef

27.

Yang X, Ko GT, So WY, Ma RC, Yu LW, Kong AP et al (2010) Associations of hyperglycaemia and insulin usage with the risk of cancer in type 2 diabetes: the Hong Kong Diabetes Registry. Diabetes 59(5):1254–1260PubMedCrossRef

28.

Libby G, Donnelly LA, Donnan PT, Alessi DR, Morris AD, Evans JM (2009) New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care 32(9):1620–1625PubMedCrossRef

29.

Yang X, Zhao H, Sui Y, Ma RC, So WY, Ko GT et al (2009) Additive interaction between renin-angiotensin system and lipid metabolism for cancer in type 2 diabetes. Diabetes 58(7):1518–1525PubMedCrossRef

30.

Yang X, Ma RC, So WY, Ko GT, Kong AP, Zhao H et al (2010) White blood cell count and renin-angiotensin system inhibitors for the risk of cancer in type 2 diabetes. Diabetes Res Clin Pract 87:117–125PubMedCrossRef

31.

Yang X, So WY, Ma RC, Yu LW, Ko GT, Kong AP et al (2010) Use of sulphonylurea and cancer in type 2 diabetes-The Hong Kong Diabetes Registry. Diabetes Res Clin Pract 90(3):343–351PubMedCrossRef

32.

Yang X, So WY, Ma RC, Yu LW, Kong AP, Lee HM, et al. (2012) Use of thiazolidinedione and cancer risk in Type 2 diabetes: the Hong Kong Diabetes Registry. Diabetes Res Clin Pract. doi:10.1016/jdiabres201203006

33.

Yang XL, Ma RC, So WY, Kong AP, Xu G, Chan JC (2012) Addressing different biases in analysing drug use on cancer risk in diabetes in non-clinical trial settings-what, why and how? Diabetes Obes Metab 14(7):579–585PubMedCrossRef

34.

Godsland IF (2010) Insulin resistance and hyperinsulinaemia in the development and progression of cancer. Clin Sci (Lond) 118(5):315–332CrossRef

35.

Cazzaniga M, Bonanni B, Guerrieri-Gonzaga A, Decensi A (2009) Is it time to test metformin in breast cancer clinical trials? Cancer Epidemiol Biomarkers Prev 18(3):701–705PubMedCrossRef

36.

Brown KA, Simpson ER (2010) Obesity and breast cancer: progress to understanding the relationship. Cancer Res 70(1):4–7PubMedCrossRef

37.

Rothman KJ, Greenland S (2005) Causation and causal inference in epidemiology. Am J Public Health 95(Suppl 1):S144–S150PubMedCrossRef

38.

Johnson JA, Bowker SL (2010) Intensive glycaemic control and cancer risk in type 2 diabetes: a meta-analysis of major trials. Diabetologia 54(1):25–31PubMedCrossRef

39.

Yang XL, Ma RC, Chan JC (2011) Meta-analysis of trial data may support a causal role of hyperglycaemia in cancer. Diabetologia 54(3):709–710PubMedCrossRef

40.

Yamasaki K, Hayashi Y, Okamoto S, Osanai M, Lee GH (2010) Insulin-independent promotion of chemically induced hepatocellular tumor development in genetically diabetic mice. Cancer Sci 101(1):65–72PubMedCrossRef

41.

Liguori A, Abete P, Hayden JM, Cacciatore F, Rengo F, Ambrosio G et al (2001) Effect of glycaemic control and age on low-density lipoprotein susceptibility to oxidation in diabetes mellitus type 1. Eur Heart J 22(22):2075–2084PubMedCrossRef

42.

Singh BM, Mehta JL (2003) Interactions between the renin-angiotensin system and dyslipidemia: relevance in the therapy of hypertension and coronary heart disease. Arch Intern Med 163(11):1296–1304PubMedCrossRef

43.

Sui Y, Zhao HL, Ma RC, Ho CS, Kong AP, Lai FM et al (2007) Pancreatic islet beta-cell deficit and glucose intolerance in rats with uninephrectomy. Cell Mol Life Sci 64(23):3119–3128PubMedCrossRef

44.

Zhao HL, Sui Y, Guan J, He L, Zhu X, Fan RR et al (2008) Fat redistribution and adipocyte transformation in uninephrectomized rats. Kidney Int 74(4):467–477PubMedCrossRef

45.

Brown MS, Goldstein JL (1997) The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell 89(3):331–340PubMedCrossRef

Titel: Synergistic effects of low LDL cholesterol with other factors for the risk of cancer in type 2 diabetes: the Hong Kong Diabetes Registry
verfasst von: Xilin Yang
Wing Yee So
Ronald C. W. Ma
Alice P. S. Kong
Heung Man Lee
Gang Xu
Risa Ozaki
Juliana C. N. Chan
Publikationsdatum: 01.12.2012
Verlag: Springer Milan
Erschienen in: Acta Diabetologica / Ausgabe Sonderheft 1/2012
Print ISSN: 0940-5429
Elektronische ISSN: 1432-5233
DOI: https://doi.org/10.1007/s00592-012-0409-y

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Sonderheft 1/2012

Are psychopathological features relevant predictors of glucose control in patients with type 2 diabetes? A prospective study

Acute and chronic fluctuations in blood glucose levels can increase oxidative stress in type 2 diabetes mellitus

Diabetes mellitus and risk of prostate cancer: an updated meta-analysis based on 12 case–control and 25 cohort studies

Gender-specific effect of physical training on AQP7 protein expression in human adipose tissue

31P-magnetic resonance spectroscopy (31P-MRS) detects early changes in kidney high-energy phosphate metabolism during a 6-month Valsartan treatment in diabetic and non-diabetic kidney-transplanted patients